newsfilter
← Latest News
PR Newswire·

Arcellx and Kite Announce Strategic Collaboration to Co-Develop and Co-Commercialize Late-Stage Clinical CART-ddBCMA in Multiple Myeloma

-- Collaboration leverages expertise across both companies, including Kite's global cell therapy leadership and industry leading reliable manufacturing -- -- Arcellx to receive $225M upfront payment; $100M equity